MedeliX
Start asking

bazedoxifene

Conbriza · ATC code G03XC02

Also known as: Bazedoxifen, Bazedoksifen

Key facts
Active substance
bazedoxifene
Drug class
Selective estrogen-receptor modulators
ATC code
G03XC02
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
CONBRIZA 20 mg film-coated tablets
Marketing authorisation holder
Pfizer Europe MA EEIG
Information as of
2026-10-29

Key facts

Bazedoxifene (Conbriza) is a selective oestrogen receptor modulator (SERM) used to treat postmenopausal osteoporosis in women at increased risk of fracture.

What it is used for

  • Treatment of postmenopausal osteoporosis in women at increased risk of fracture.
  • A significant reduction in vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.

Dosing

  • One 20 mg tablet once daily, at any time of day, with or without food.
  • Doses higher than 20 mg are not recommended.
  • Add supplemental calcium and/or vitamin D if dietary intake is inadequate.
  • No dose adjustment in mild or moderate renal impairment or based on age; caution in severe renal impairment; not recommended in hepatic impairment.

Contraindications

  • Hypersensitivity to the active substance or any excipient.
  • Active or past venous thromboembolic events (deep vein thrombosis, pulmonary embolism, retinal vein thrombosis).
  • Women of child-bearing potential.
  • Unexplained uterine bleeding; signs or symptoms of endometrial cancer.

Important warnings

  • Increased risk of venous thromboembolism, highest in the first year of treatment; not recommended in women at increased VTE risk.
  • Discontinue before and during prolonged immobilisation and resume only when fully ambulatory.
  • Any uterine bleeding during therapy is unexpected and should be fully investigated.
  • May increase serum triglycerides; caution in known hypertriglyceridaemia.
  • Not studied or not recommended in premenopausal women and in breast cancer.

Side effects

  • Most frequent: hot flushes and muscle spasms (including leg cramps); mostly mild to moderate.
  • Others: hypersensitivity, somnolence, dry mouth, urticaria, rash, pruritus, peripheral oedema, increased triglycerides and liver enzymes.
  • Serious: deep vein thrombosis, pulmonary embolism, retinal vein thrombosis.

Interactions

  • UGT inducers such as rifampicin, phenobarbital, carbamazepine and phenytoin may lower bazedoxifene concentrations.
  • Little or no CYP-mediated metabolism; increases hormone-binding globulins (CBG, SHBG, TBG).

Pregnancy and breastfeeding

  • Only for postmenopausal women; contraindicated in women of child-bearing potential. Should not be used during breast-feeding.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • ConbrizaPfizer Europe MA EEIG · EMEA/H/C/000913

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Conbriza
Liechtenstein
Conbriza
Norway
Conbriza

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Conbriza – EPAR, Product Information. 2026-10-29. https://www.ema.europa.eu/en/documents/product-information/conbriza-epar-product-information_en.pdf
  2. Wikidata (CC0): ATC G03XC.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.